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ABSTRACT 
A number of marketed antibacterial drugs suffer several problems, 
such as bitter sensation and low stability which lead to patient 
incompliance. The prodrug approach is considered the most promising 
and extremely exciting method to overcome such problems. Based on 
our previously reported density functional theory (DFT) calculations, 
amoxicillin ProD 1-2 and cephalexin ProD 1-2 were designed, 
synthesized and fully characterized. The intraconversion kinetics for 
amoxicillin ProD 1-2 and cephalexin ProD 1-2 were carried out in 
different aqueous media and the kobs and t1/2 values for the four 
prodrugs were calculated from a linear regression equation obtained 
from the plot of log concentration of the residual prodrug versus time. 
Kinetic studies in 1N HCl, pH 2.5 and pH 5 were selected to examine  
the intraconversion for the prodrugs to their active parent drugs. The intraconversion of the 
prodrugs to their active parent drugs was found to be much higher in 1N HCl than in pH 2.5 
and pH 5. The experimental t1/2 values of amoxicillin ProD 1 in 1N HCl, pH 2.5 and pH 5 
were 2.5, 7 and 81 hours, respectively, and for cephalexin ProD 1 in 1 N HCl and pH 2.5 
were 2 and 14 hours, respectively. On the other hand, the t1/2 values of amoxicillin ProD 2 in 
1N HCl and pH 2.5 were 8 and 44 hours, respectively, and for cephalexin ProD 2 in 1 N HCl 
was 6 hours. At pH 7.4, the four prodrugs were quite stable and no release of the parent drugs 
was observed. At pH 5 the hydrolysis of the prodrugs was too slow. In vitro binding test 
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revealed that the four antibacterial prodrugs were bitterless and it is believed that the lack of 
the bitter sensation is due to the disability of the prodrugs to interact with the active sites of 
the tested bitter taste receptors.  
 
KEYWORDS: Prodrugs, bitterness, antibacterials, amoxicillin, cephalexin, enzyme model, 
DFT calculations, Kirby‘s N-alkylmaleamic acids. 
 
1. INTRODUCTION 
1.1 Background 
The palatability of the drug‘s active ingredient is considered a major obstacle in the 
development of a patient friendly dosage form. Organoleptic properties, such as odor and 
taste are crucial factors in the selection of a certain medicine from the available generic 
medicines available in the pharmaceutical market and having the same active ingredient. The 
drug‘s taste is a key issue for doctors and pharmacists when prescribing a medicine for 
pediatric and geriatric patients. Consequently, the pharmaceutical industries are recognizing 
the vast importance in masking the unpleasant taste of drugs and a significant number of 
methods and approaches have been invoked for concealing the objectionable taste of drugs.
[1]
  
 
A respected number of marketed antibacterial drugs such as amoxicillin, cephalexin, 
cefuroxime axetil, azithromycin and others suffer various problems and the most striking 
drawbacks are their low stability in suspension formulation and their bitter sensation which 
lead to serious patient incompliance. Bitter tastant molecules interact with taste receptors on 
the tongue to give bitter sensation. Thus, modification on their structural features might 
provide a solution to overcome this obstacle. 
 
It is believed that amoxicillin‘s and cephalexin‘s bitterness is a result of hydrogen bonding 
between their free amino groups and the amino acids contained in the active sites of the bitter 
taste receptors.  
 
Therefore, it is quite reasonable to assume that a design and synthesis of prodrugs to replace 
bitterness antibacterials could increase the patient compliance to antibacterials formulated in 
solution or syrup dosage forms by reducing or eliminating their bitterness as a result of 
altering the ability of the antibacterial agent to interact with the active sites of the bitter taste 
receptors.  
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It is well known that a large number of therapeutic agents have pharmacological and/or 
pharmacokinetic barriers, such as low oral absorption, lack of site selectivity, chemical 
instability, toxicity and poor patient compliance (unpleasant taste, odor, pain at injection site 
and etc.). The prodrug approach is widely considered among the best approaches to minimize 
the undesirable properties of a drug while retaining its desirable therapeutic activity. This 
approach is useful in the optimization of the clinical application of most of the marketed 
drugs.
[2-4] 
 
Prodrugs are bioreversible pharmacologically inactive molecules that prior to exerting the 
desired pharmacological effect they undergo in vivo enzymatic and/or chemical 
transformation to their active parent drugs. The prodrug approach is becoming more 
successful and popular. Nowadays, prodrugs comprise about tenth of the world‘s marketed 
medications and fifth of all medications with small molecular weight approved in 2000-
2008.
[2-4] 
 
1.2 Bitter Taste of Drugs 
Several techniques based on physical modifications of active parent drugs have been 
investigated and revealed to the development of new methods for masking the unpleasant 
taste of a variety of pharmaceuticals. Some of these techniques include: (1) taste masking 
with flavors, sweeteners, and amino acids 
[5]
 such as the use of monosodium glycyrrhizinate 
with flavors to mask the bitter taste of guaifenesin, (2) taste masking with lipophilic vehicles 
such as lipids, lecithin, and lecithin- like substances 
[6]
 such as the one composed of 
magnesium aluminum silicate with soybean lecithin and talampicillin HCl, (3) coating is one 
of the most efficient and commonly used taste masking techniques. An example of such 
method is masking the taste of famotidine (a drug for ulcer treatment) by using a combination 
of water soluble polymers such as polyvinylpyrrolidone, and insoluble polymers, such as 
cellulose acetate, 
[7]
 (4) microencapsulation processes based on the principle of solvent 
extraction or evaporation, 
[8]
 (5) sweeteners are generally used in combination with other taste 
masking technologies,
[9]
 (6) taste suppressants and potentiators, such as Linguagen‘s bitter 
blockers (e.g. adenosine monophosphate): are used for masking the bitter taste of various 
compounds by competing with binding to the G-protein coupled receptor sites (GPCR): 
[10]
 
(7) resins are used to mask bitter tastants by forming insoluble resinates through weak ionic 
bonding with oppositely charged drugs. 
[11]
 An example for such technique is the ion 
exchange resin amberlite which is used to formulate taste masked, fast dissolving, and orally 
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consumable films of dextromethorphan (a cough suppressant): 
[12]
 (8) inclusion complexes, 
the drug molecule fits into the cavity of a complexing agent and forms a stable complex that 
masks the bitter taste of a drug by decreasing its oral solubility, 
[13]
 (9)  pH modifiers are 
capable of generating a specific pH microenvironment in aqueous media that has the ability 
to facilitate precipitation of the bitter drug compound in saliva thus reducing the overall taste 
sensation for liquid dosage forms, 
[14]
 (10)  adsorbates, the compound may be adsorbed or 
entrapped in the matrix of the adsorbate pore, which may result in a delayed release of the 
bitter tastant during passage through the oral cavity and mask the taste. 
[15] 
 
These masking methods have succeeded to overcome or eliminate the unpleasant taste of a 
number of drugs dosage forms, however, the problem of the bitter sensation of commonly 
used drugs given to pediatrics and geriatrics still imposes a significant challenge to the health 
community. Therefore, there is a pressing need to new approaches to be developed for 
solving this serious problem.  
 
In the past seven years we have developed a novel prodrugs chemical approach which 
involves the design of prodrugs for drugs having poor bioavailability, low aqueous solubility, 
inefficient permeation or unpleasant (bitter) taste. This approach is based on intramolecularity 
using quantum mechanics (QM) such as density functional theory (DFT) and ab initio 
methods 
[16]
 and correlations of experimental and calculated activation energies (reaction‘s 
rate). In this approach, no enzyme is involved in the the interconversion of the prodrug to its 
active parent drug. The release of the active drug from its prodrug is determined and 
programmed according to the nature (chemical features) of the promoiety bound to the active 
parent drug. For instance, bitter tastants or drugs interact with the taste receptors located on 
the tongue to give their bitter taste. Altering the ability and capability of the active drug to 
interact with the active site/s of the bitter taste receptor/s might have the potential to reduce or 
completely eliminate its bitterness. This masking can be accomplished by an appropriate 
modification of the structural features and size of the bitter tastant. Generally, bitter tastant 
binds to the G-protein coupled receptor-type T2R on the apical membrane of the taste 
receptor located in the taste buds. 
[17,18] 
 
It is worth noting that the classic prodrug approach is focused on altering various 
physiochemical parameters and the interconversion of the prodrug to its active form is 
usually occur with the involvement of metabolic enzymes such as esterases, amidases, 
phosphatases or cyctochromes, whereas our novel computational approach, considers a 
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design of promoieties to be covalently linked to the active drugs and upon reaching the 
physiological target the prodrug undergoes a controlled intraconversion to a non-toxic moiety 
and its active parent drug without the need of metabolic enzymes.  
 
1.3 Enzyme Models As Prodrugs Linkers  
During the past 60 years a respected number of studies were carried out by several chemists 
and biochemists for understanding how enzymes catalyze biotransformation reactions.  
 
The findings of these studies revealed that enzyme catalysis is based on the combined effects 
of the catalysis by functional groups and the ability to reroute intermolecular reactions 
through alternative pathways by which substrates can bind to preorganized active sites. 
Enzymatic reactions‘ rates are in the range of 1010 and 1018 fold their non-enzymatic 
bimolecular counterparts. For example, the biotransformation reactions catalyzed by the 
enzyme cyclophilin are accelerated by10
5
 and those by the enzyme orotidine monophosphate 
decarboxylase are enhanced by 10
17
. 
[19] 
 
Among the scholarly studies that have been devoted to assign the factors playing dominant 
roles in enzymes catalysis are those done by Bruice, Cohen, Menger and Kirby in which 
novel enzyme models were invoked and the rate accelerations in such models have been 
proved to be driven by covalently enforced proximity. The most striking example for such 
models is the one done by Bruice et al. which involves intramolecular cyclization of 
dicarboxylic semi esters to yield anhydrides. 
[20,21]
 Bruice‘s study revealed that a relative rate 
of anhydride formation can reach 5 x 10
7
 upon cyclization of a dicarboxylic semi ester when 
compared to a similar counterpart‘s intermolecular reaction. Other examples of enzyme 
models in which the rate enhancements are due to proximity orientation include: (i) acid-
catalyzed cyclization of hydroxy-acids as researched by Cohen et al. 
[22-24]
 and Menger, 
[25-32]
 
(ii) SN2-based ring-closing reactions as studied by Brown et al. 
[33]
 and Mandolini‘s group, [34] 
(iii) proton transfers between two oxygens in Kirby‘s acetals [33-41] and between nitrogen and 
oxygen in Kirby‘s enzyme models, [33-41] (iv) proton transfer between two oxygens in rigid 
systems as reported by Menger, 
[25-32]
 and (v) proton transfer between oxygen and carbon in 
some of  Kirby‘s enol ethers.[33-41] The conclusions emerged from these studies are (a) 
entropy and enthalpy factors are the driving force for accelerations in rate for intramolecular 
processes. In ring-closing and proton transfer processes, proximity or/and steric effects were 
the driving force for rate accelerations, and the enthalpy factor was predominant. (b) The 
nature of the reaction being intermolecular or intramolecular is dependent on the distance 
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between the nucleophile and electrophile (the two reacting centers). (c) An effective proton 
transfer between two oxygens and between nitrogen and oxygen in Kirby‘s enzyme models 
were accessible when a strong hydrogen bonding net was formed in the products and the 
transition states leading to them. 
[42-64]
 
 
Using DFT, ab initio and molecular mechanics methods we have computed the following 
intramolecular processes (enzyme models): (1) lactonization of dicarboxylic semi-esters to 
the corresponding anhydrides as explored by Bruice and Pandit, (2) acid-catalyzed 
cyclization of hydroxy-acids as studied by Cohen et al., (3) proton transfers between two 
oxygens and between nitrogen and oxygen in Kirby‘s enzyme models, (4) acid-catalyzed 
hydrolysis of N-alkylmaleamic acids as researched by Kirby et al. and (5) proton transfer 
between two oxygens in Menger‘s rigid hydroxy-acids.  
 
The results emerged from the above mentioned computational studies have been utilized for 
the design of innovative prodrugs for commonly used drugs containing amine, hydroxyl and 
phenol functional groups in their structures. 
[65-98]
 
  
For example, unraveling the mechanism of the proton transfer reaction in Kirby‘s enzyme 
model (acetals) 
[99]
 has revealed to a design and synthesis of several novel prodrugs such as 
those of aza-nucleosides for the treatment of myelodysplastic syndromes,
[82]
 atovaquone to 
treat malaria cases 
[86-88, 100]
 and statins (simvastatin and atorvastatin) to  reduce cholesterol 
levels in the blood circulation. 
[83]
 In these examples, the promoiety of the prodrug was 
attached to the acetal‘s hydroxyl group present in the active drug form such that the prodrug 
chemical device has the potential to undergo chemical cleavage once it reaches the 
physiological target such as the stomach, intestine, and systemic blood circulation, with rates 
that are solely determined by the chemical features of the pharmacologically inactive linker 
(Kirby‘s enzyme model). Other different linkers such as Kirby‘s N-alkylmaleamic acids 
enzyme model 
[48]
 was also exploited for the design of a variety of prodrugs such as those of 
tranexamic and 6-aminocaproic acids for the treatment of bleeding conditions 
[84]
 and the 
antiviral agent acyclovir to treat Herpes Simplex, [85] the anti-hypertensive agent, atenolol 
[92-93]
 and the antimalarial agent, atovaquone. 
[86-88, 100]
 Another enzyme model which was 
exploited for the design of dopamine prodrugs for the treatment of Parkinson‘s disease is 
Menger‘s Kemp acid enzyme model. [89] Prodrugs for monoalkyl and dialkyl (monomethyl 
and dimethyl) fumarates for the treatment of multiple sclerosis and psoriasis were also 
designed, synthesized and their in vitro and in vivo kinetics are under investigation. 
[90]
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Furthermore, this approach was also utilized for masking the bitter sensation of the 
antibacterial agent, cefuroxime axetil, 
[94]
 the antihypertensive agent, atenolol, 
[92-93]
 and the 
pain killer agent, paracetamol. 
[91]
 The role of the promoiety in cefuroxime axetil, atenolol 
and paracetamol prodrugs is to block the free amine or the hydroxyl group, which is believed 
to be responsible for the drug bitter sensation, and to provide a slow release of the active drug 
from its prodrug. In the case of atenolol and cefuroxime axetil, the difference between the 
designed prodrugs and their active forms is that the amine group in the active parent drug is 
replaced with the more stable amide group. It is quite reasonable to assume that replacement 
of the free amine moiety in the active drugs with an amide group will have the potential to 
eliminate or reduce significantly the capability of the prodrug to form hydrogen bonding with 
the amino acids contained in the active site/s of the bitter taste receptors, thus masking the 
bitter sensation of the parent drug. For example, paracetamol used for alleviating pain and 
reducing fever has a very strong bitter taste. On the other hand, phenacetin, a pain killer 
which was withdrawn from the market lacks or has very weak bitter sensation. The chemical 
difference between both drugs is only in the group in the para position of the benzene ring. In 
the case of paracetamol the para position is occupied by a hydroxyl group, whereas in 
phenacetin the group is ethoxy. Another analgesic and antipyretic drug which was withdrawn 
from the market due to its toxicity is acetanilide, has a chemical structure similar to that of 
paracetamol and phenacetin but possess a hydrogen atom in the para position of the benzene 
ring, however, it is quite lack the bitter sensation characteristic of paracetamol. These 
observations suggest that the hydroxyl moiety on the para position of paracetamol is the main 
contributor for its bitter sensation. It is believed that its bitterness is due to the hydrogen 
bonding interactions between its hydroxyl and the amino acids located at the active site of the 
bitter taste receptors. Substituting the phenolic hydroxyl of paracetamol with a chemical 
group lacking the capability of forming hydrogen bonding with the receptor active site is 
expected to significantly reduce its binding to the receptor and hence to eliminate its 
bitterness. In a similar manner, blocking the free amine moiety in atenolol, cefuroxime or any 
penicillin derivatives containing free amine group such as amoxicillin or cephalexin with a 
suitable promoiety will have the potential to inhibit the interaction between the prodrug and 
its bitter taste receptors and hence masks its bitter sensation.  
 
In this manuscript, we have implied this novel prodrug approach in the design of amoxicillin 
and cephalexin prodrugs using molecular orbital and molecular mechanics methods and 
correlations between experimental and calculated rate values for Kirby‘s N-alkylmaleamic 
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acids process. In this approach, no enzyme is needed to catalyze the conversion of 
amoxicillin or cephalexin prodrugs to their corresponding active parent drugs.  
 
The use of this approach has the potential to eliminate all disadvantages associated with 
prodrugs interconversion catalyzed by metabolic enzymes. The in vivo interconversion of 
prodrugs is considered the most vulnerable link in the chain, since there are a variety of 
intrinsic and extrinsic factors that might affect the process. For instance, the therapeutic 
profile efficiency of many prodrugs catalyzed by enzymes may be varied due to genetic 
polymorphisms, age-related physiological changes, or drug interactions, leading to adverse 
pharmacokinetic, pharmacodynamic, and clinical effects. Furthermore, there are wide 
interspecies variations in the expression and function of the major metabolic enzymes, and 
these might pose some obstacles in the preclinical optimization stage. 
 
1.4 Amoxicillin                                                                                                                                                      
Amoxicillin is a β-lactam antibiotic (Figure 1): semi-synthetic penicillin which has a 
moderate-spectrum, used orally to treat infections caused by susceptible microorganisms by 
which it  is susceptible to the action of the β-lactamases. Amoxicillin has a bactericidal action 
and acts against both Gram positive and Gram-negative bacteria by inhibiting the 
biosynthesis and repair of the bacterial mucopeptide wall. It is considered the drug of choice 
within its class since it is well absorbed after oral administration. Amoxicillin is mostly 
common antibiotics prescribed for children. It has high absorption after oral administration 
which is not affected by the presence of food. Amoxicillin dose reaches Cmax about 2 hours 
after administration and is quickly distributed and eliminated by excretion in urine (about 
60%- 75%). The antibacterial effect of amoxicillin is extended by the presence of a benzyl 
ring in the side chain. Because amoxicillin is susceptible to degradation by β-lactamase-
producing bacteria, which are resistant to a broad spectrum of β-lactam antibiotics, such as 
penicillin, for this reason, it is often combined with clavulanic acid, a β-lactamase inhibitor. 
This increases effectiveness by reducing its susceptibility to β-lactamase resistance. 
Amoxicillin has two ionizable groups in the physiological range (the amino group in α-
position to the amide carbonyl group and the carboxyl group). Amoxicillin has a good 
pharmacokinetics profile with bioavailability of 95% if taken orally, its half-life is 61.3 
minutes and it is excreted by the renal and less than 30 % is biotransformed in the                           
liver. 
[101-104]
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1.5 Cephalexin 
Cephalexin is a first-generation cephalosporin antibiotic (Figure 2): which has been selected 
as the drug of choice to obtain dosage with improved stability, better palatability and more 
attractive to pediatrics, cost effective and easy to be administered. Cephalexin is widely used 
for treatment of skin infections due to its safety profile, and its wide range of activity against 
both gram positive and gram negative bacteria. Cephalexin is also used for the treatment of 
articular infections as a rational first-line treatment for cellulitis, it is a useful alternative to 
penicillins hypersensitivity, and  thought to be safe in a patient with penicillin allergy but 
caution should always be taken, that‘s because cephalexin and other first-generation 
cephalosporins are known to have a modest cross-allergy in patients with penicillin 
hypersensitivity. Cephalexin‘s mechanism of action is by interfering with the bacteria's cell 
wall formation, causing it to rupture, and thus killing the bacteria. Cephalexin is zwitterion by 
which it contains both a basic and an acidic group, its isoelectric point in water is 
approximately 4.5 to 5.  This antibacterial agent has a good pharmacokinetic profile by which 
it is well absorbed, 80% excreted unchanged in urine within 6 hours of administration. Its 
half-life is 0.5-1.2 hours and it is excreted via the renal. It is used for the treatment of 
infections including otitis media, streptococcal pharyngitis, bone and joint infections, 
pneumonia, cellulitis and UTI, and so it may be used to prevent bacterial endocarditis. 
[105-108]
 
 
The major problems in the administration of amoxicillin and cephalexin antibacterial drugs 
are: (1) the low stability in suspension formulation. These medications are very labile 
molecules when are exposed to aqueous media. They might undergo hydrolysis when they 
are standing in solutions. The main cause of their degradation is the reactivity of the strained 
lactam ring particularly towards hydrolysis, the course of the hydrolysis and the nature of the 
degradation products are influenced by the pH of the solution. The lactam‘s carbonyl group 
in both drugs readily undergoes nucleophilic attack by water and especially hydroxide ion to 
form the inactive penicilloic acid and (2) their bitter sensation which leads to lack of patient 
compliance and might create a serious challenge to the pharmacist in pediatrics and geriatrics 
formulations. 
 
2-Experimental Part 
2.1 Calculations Methods  
The DFT calculations at B3LYP/6-31G (d,p) and B3LYP/311+G (d,p) levels were carried out 
using the quantum chemical package Gaussian-2009. 
[109]
 The starting geometries of all the 
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molecules presented in this study were obtained using the Argus Lab program 
[110]
 and were 
initially optimized at the AM1 level of theory, followed by an optimization at the HF/6-31G 
level. The calculations were carried out based on the restricted Hartree-Fock (RHF) method 
with full optimization of all geometrical variables. An energy minimum (a stable compound 
or a reactive intermediate) has no negative vibrational force constant. A transition state is a 
saddle point which has only one negative vibrational force constant. The ―reaction coordinate 
method‖ was used to calculate the activation energy in systems 1-9; [111-112] in this method, 
one bond length is constrained for the appropriate degree of freedom while all other variables 
are freely optimized. The activation energy values for the approach processes were calculated 
from the difference in energies of the global minimum structures and the derived transition 
states. Similarly, the activation energies of the dissociation processes were calculated from 
the difference in energies of the global minimum structures and the corresponding transition 
states. Verification of the desired reactants and products was accomplished using the 
―intrinsic coordinate method‖. The transition state structures were verified by their only one 
negative frequency.
  
Full optimization of the transition states was accomplished after 
removing any constrains imposed while executing the energy profile. The activation energies 
obtained from DFT at B3LYP/6-31G (d,p) level of theory for 1-9 were calculated with and 
without the inclusion of solvent (water). The calculations with the incorporation of a solvent 
were performed using the integral equation formalism model of the Polarizable Continuum 
Model (PCM); 
[113-116]
 in this model the cavity is created via a series of overlapping spheres. 
The radii type employed was the United Atom Topological Model on radii optimized for the 
PBE0/6-31G (d) level of theory. 
 
2.2 Experimental 
Inorganic salts were of analytical grade and were used without further purification. Organic 
buffer components were distilled or recrystallized. Distilled water was redistilled twice before 
use from all-glass apparatus. Maleic anhydride, succinic anhydride, anhydrous sodium 
dihydrogen phosphate, sodium lauryl sulfate, triethyl amine, amoxicillin and cephalexin were 
commercially obtained from Sigma Aldrich. HPLC grade solvents of methanol, acetonitrile 
and water were purchased from Sigma Aldrich. High purity dichloromethane, ethyl acetate, 
THF and diethyl ether (> 99%) were purchased from Biolab (Israel). The LC/ESI-MS/MS 
system used was Agilent 1200 series liquid chromatography coupled with a 6520 accurate 
mass quadruple-time of flight mass spectrometer (Q-TOF LC/MS). The analysis was 
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performed in the positive electrospray ionization mode. The capillary voltage was 4.0 kV, the 
scanned mass range was 200-540 m/z (MS).  
 
The high pressure liquid chromatography (HPLC) system consisted of an Alliance 2695 
module equipped with 2996 Photodiode array detector from Waters (Germany). Data 
acquisition and control were carried out using Empower 2 ™ software (Waters, Germany). 
Analytes were separated on a 4.6 mm x150 mm XBridge® C18 column (5 μm particle size) 
used in conjunction with a 4.6 x 20 mm, XBridge® C18 guard column. Microfilters of 
0.45μm porosity were normally used (Acrodisc® GHP, Waters). pH meter model HM-30G: 
TOA electronics™ was used in this study to measure the pH value for the buffers. The Sep-
Pack C18 6cc (1 g) cartridges were purchased form Waters (Milford, MA, USA).  
1
H-NMR 
experiments were performed with a Bruker AvanceII 400 spectrometer equipped with a 5 mm 
BBO probe. All infrared spectra (FTIR) were obtained from a KBr matrix (4000–400 cm-1) 
using a PerkinElmer Precisely, Spectrum 100, FT-IR spectrometer.  
 
2.2.1 Preparation of amoxicillin ProD 1-2 (Figure 1)  
Amoxicillin ProD 1: In a 250 ml round-bottom flask, 2.12 g of amoxicillin trihydrate (5 
mmol) was dissolved in 100 ml H2O, 0.45 g of sodium bicarbonate was added and the 
resulting solution was stirred for 30 minutes, then 0.5 g of maleic anhydride (5 mmol) was 
slowly added to the reaction mixture. The pH of the mixture was adjusted to 7. The reaction 
mixture was stirred at room temperature for 2 hours and the progress of the reaction was 
monitored by TLC. The reaction‘s solvent was evaporated using rotary evaporator and the 
resulting precipitate was washed with ethyl acetate and filtered. The white precipitate formed 
was dissolved in methanol, filtered, evaporated and dried at 39˚C to yield 2.6 g. M.P. 170 ˚C; 
1
H-NMR δ (ppm) CD3OD: 1.5 (m, 6H, CH3-C-CH3): 4.2 (d, 1H, J=20 Hz, HN-CH-CH-S,): 
4.7 (s, 1H, N-CH-COOH): 5.0 (d, 1H, J=4 Hz, HC-CH-S-C): 5.4 (d, 1H, J=6.4 Hz, NH-CH-
C): 5.5 (d, 1H, J=20 Hz, NH-CH-(Ar)): 6.3 (d, 1H, J=10.4 Hz, HOOC-CH=CH-C=O): 6.7 (d, 
1H, J=10.4 Hz, HC-CH=C-CH=C): 6.8 (m, 2H, aromatic): 7.3 (m, 2H, aromatic); IR 
(KBr/νmax cm
–1
) 1763 (C=O): 1650, 1585, 1369, 1246; m/z 486.1 (M+1). 
 
Amoxicillin ProD 2: the same procedure was followed as for amoxicillin ProD 1 but instead 
of using maleic anhydride, 0.5 g (5 mmol) succinic anhydride was used (product; 2.8 g as a 
white solid). M.P. 147-150 ˚C; 1H-NMR δ (ppm) CD3OD: 1.5 (m, 6H, CH3-C-CH3): 2.5 (m, 
4H, COOH-CH2-CH2-C=O): 3.4 (d, 1H, J=5.6 Hz, HC-CH-S-C): 4.2  (s, 1H, N-CH-COOH): 
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4.9 (s, 1H, HN-(C=O)-CH-Ar): 5.4 (d, 1H, J=4 Hz, NH-CH-C=O): 6.9 (m, 2H, aromatic): 7.3 
(m, 2H, aromatic); IR (KBr/νmax cm
–1
) 1769 (C=O): 1576, 1514, 1402; m/z 488.1 (M+1). 
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Figure 1: Schematic representation for the synthesis of amoxicillin ProD 1-2 from its 
parent drug, amoxicillin, and an anhydride. 
 
2.2.2 Preparation of cephalexin ProD 1-2 (Figure 2)  
Cephalexin ProD 1: In a 250 ml round-bottom flask, 1.75 g of cephalexin standard (5 mmol) 
was dissolved in 100 ml H2O, 0.45 g of sodium bicarbonate was added and the resulting 
solution was stirred at room temperature, then 0.52 g of maleic anhydride (5 mmol) was 
slowly added to the reaction mixture. The pH of the reaction was maintained at pH 7, then 
was stirred for 2 hours at room temperature and was monitored by TLC. The reaction‘s 
solvent was evaporated by rotary evaporator to dryness, and the resulting residue was washed 
with ethyl acetate.  The solid residue obtained was dissolved in 50 ml methanol, dried over 
MgSO4, filtered and evaporated. The resulting white precipitate was collected and dried at 
39˚C to yield 2.9 g. M.P. 156-160 ˚C; 1H-NMR δ (ppm) CD3OD: 1.5 (s, 3H, CH3-C=C): 3.3 
(s, 2H, S-CH2-C=C): 4.9 (s, 1H, C-CH-C=O): 4.95 (s, 1H, NH-CH-C=O): 5.5 (d, 1H, J= 12.8 
Hz, S-CH-CH-NH): 5.6 (d, 1H, J= 12.8 Hz, NH-CH-CH): ): 6.23 (d, 1H, J = 12.8 Hz, 
HC=CH): 6.30 (d, 1H, J = 12.8 Hz, HC=CH): 7.3-7.5 (m, 5H, aromatic); IR (KBr/νmax cm
–1
) 
1758 (C=O): 1674, 1578, 1249; m/z 468 (M+1).  
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Cephalexin ProD 2: the same procedure was followed as for the preparation of cephalexin 
ProD 1 but instead of using maleic anhydride, 0.52 g (5 mmol) of succinic anhydride were 
used (yield; 2.0 g.). M.P. 240 ˚C; 1H-NMR δ (ppm) CD3OD: 2.05 (s, 3H, CH3-C=C): 2.5 (m, 
4H, COOH-CH2-CH2-C=O): 3.03 (d, 1H, J=12.6 Hz, NH-CH-CH-N-C): 3.2 (d, 1H, J=12.6 
Hz, NH-CH-CH-S, 3.3 (s, 2H, S-CH2-C=C): 4.9 (s, 1H, NH-CH-C=O): 5.5 (s, 1H, Ar-CH-
C=O): 7.3-7.6 (m, 5H, aromatic). IR (KBr/νmax cm
–1
) 1755 (C=O): 1665, 1586, 1255; m/z 470 
(M+1).  
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Figure 2: Schematic representation for the synthesis of cephalexin ProD 1-2 from its 
parent drug, cephalexin, and an anhydride. 
 
2.2.3 Kinetic Methods  
The intraconversion of 500 ppm amoxicillin ProD 1-2 solutions, in 1N HCl, buffer pH 2.5, 
buffer pH 5.0 and buffer pH 7.4, to their parent drug, amoxicillin, was run at 37.0 ˚C and 
followed by HPLC at a wavelength of 254 nm for amoxicillin ProD 1 and 230 nm for 
amoxicillin ProD 2.  
 
The intraconversion of 500 ppm cephalexin ProD 1-2 solution, in 1N HCl, buffer pH 2.5, 
buffer pH 5.0 and buffer pH 7.4, to their parent drug, cephalexin, was run at 37.0 ˚C and 
followed by HPLC at a wavelength of  230 nm.  
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3. RESULTS AND DISCUSSION  
3.1 Kirby’s N-alkylmaleamic acids enzyme model  
Kirby et al. have studied the acid-catalyzed hydrolysis of N-alkylmaleamic acids 1-9 (Figure 
3) 
[41]
 and found that the amide in 1-9 is cleaved due to intramolecular nucleophilic catalysis 
by the adjacent carboxylic acid group and the rate-limiting step of the reaction is the 
dissociation of the tetrahedral intermediate. 
[35-41, 99] 
 
For exploiting Kirby‘s intramolecular process [35-41, 99] for the design of amoxicillin and 
cephalexin prodrugs we have explored the mechanism of the intramolecular acid- catalyzed 
hydrolysis of 1-9 using DFT calculation methods at both B3LYP/6-31G (d,p) and 
B3LYP/311+G (d,p) levels. The DFT calculations demonstrated that the reaction proceeds by 
three steps: (i) proton transfer from the carboxylic acid group to the amide carbonyl oxygen, 
(ii) nucleophilic attack of the carboxylate onto the protonated carbonyl carbon; and (iii) 
dissociation of the tetrahedral intermediate to yield products. Additionally, the calculations 
revealed that the efficiency is significantly sensitive to the pattern of substitution on the 
carbon–carbon double bond. Further, it was found that the hydrolysis rate is linearly 
correlated with the strain energy of the reaction‘s tetrahedral intermediate or product. 
Systems having unstrained tetrahedral intermediates or products are characterized with high 
rates and vice versa. 
[42-65]                                                                                                                     
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Figure 3: Acid-catalyzed hydrolysis of maleamic acids 1-9. 
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3.2 Hydrolysis studies  
Based on the DFT calculations and experimental data for the acid-catalyzed hydrolysis of 
amide acids 1-9 (Figure 3): 
[41, 48]
 four amoxicillin and cephalexin prodrugs were proposed 
utilizing two different linkers (Figures 4 and 5, respectively). As shown in Figures 4 and 5, 
the antibacterial prodrugs, amoxicillin ProD 1-2 and cephalexin ProD 1-2 are composed of a 
promoiety containing a carboxylic acid group (hydrophilic moiety) and the rest of the 
prodrug molecule (a lipophilic moiety).    
                                                                                                                                                                                                                                              
N
S
O
OH
O
H
N
H
O
HN
HO
N
S
O
OH
O
H
N
H
O
NH2
HO
O
O
O
OH
O
O
H2O
Amoxicillin ProD 1
Maleic anhydride
Amoxicillin
OH
O
O
OH
Maleic acid
N
S
O
OH
O
H
N
H
O
HN
HO
N
S
O
OH
O
H
N
H
O
NH2
HO
O
O
O
OH
O
O
H2O
Amoxicillin ProD 2
Succinic anhydride
Amoxicillin
OH
O
O
OH
Succinic acid
 
Figure 4: Intraconversion of amoxicillin ProD 1-2 to their parent drug, amoxicillin. 
 
The combination of the hydrophilic and lipophilic groups provides a chemical device with a 
moderate HLB value that has the potential to be effectively permeated through membranes. It 
is worth noting, that the HLB value of the prodrug will be determined on the pH of the 
target‘s physiological environment. In the stomach where the pH is 1-2, it is expected that 
amoxicillin ProD 1-2 and cephalexin ProD 1-2 will be in the free carboxylic acid forms (a 
relatively high hydrophobicity) whereas in the blood stream circulation where the pH is 7.4 
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the carboxylate anion form (a relatively high hydrophilicity) will be the predominant. Our 
approach was to synthesize amoxicillin ProD 1-2 and cephalexin ProD 1-2 as sodium or 
potassium salts due to their high stability in neutral aqueous medium. It should be 
emphasized that 1-9 undergo a relatively fast hydrolysis in acidic media whereas they are 
quite stable at neutral pH.     
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Figure 5: Intraconversion of cephalexin ProD 1-2 to their parent drug, cephalexin. 
 
The designed four prodrugs, amoxicillin ProD 1-2 and cephalexin ProD 1-2 were 
successfully synthesized, according to the schemes shown in Figures 4 and 5, and fully 
characterized (see experimental section).  
 
The release of the antibacterial agents, amoxicillin and cephalexin, from their corresponding 
prodrugs, amoxicillin ProD 1-2 and cephalexin ProD 1-2 were carried out in aqueous buffers 
using the same procedure of Kirby et al. on N-alkylmaleamic acids 1-9 and the kinetics were 
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followed by HPLC. This is to investigate whether the antibacterial prodrugs undergo 
hydrolysis in aqueous medium and to what extent, suggesting the fate of the prodrugs in the 
system. The kinetics for amoxicillin ProD 1-2  and cephalexin ProD 1-2 were carried out in 
four different aqueous media: 1 N HCl, buffer pH 2.5, buffer pH 5 and buffer pH 7.4. Under 
the experimental conditions the four antibacterial prodrugs intraconverted to release the 
parent drugs (Figures 4-5) as was determined by HPLC analysis. For amoxicillin and 
cephalexin prodrugs, at constant temperature (37  C) and pH the hydrolysis reaction displayed 
strict first order kinetics as the kobs was quite constant and a straight line was obtained on 
plotting log concentration of residual prodrug verves time. kobs and the corresponding t1/2 for 
amoxicillin ProD 1-2 and cephalexin ProD 1-2 in the different media were calculated from 
the linear regression equation obtained from the correlation of log concentration of the 
residual prodrug verses time. The kinetic data for amoxicillin ProD 1-2 and cephalexin ProD 
1-2 are listed in Tables 1-2. It is worth noting that 1N HCl and pH 2.5 were selected to 
examine the intraconversion of amoxicillin ProD 1-2 and cephalexin ProD 1-2 in the pH as 
of stomach, since the mean fasting stomach pH of adult is approximately 1-3. Furthermore, 
environment of buffer pH 5 mimics that of beginning small intestine route, whereas pH 7.4 
was selected to determine the intraconversion of the tested prodrugs in the blood circulation 
system. Acid-catalyzed hydrolysis of amoxicillin ProD 1-2 and cephalexin ProD 1-2 was 
found to be much higher in 1N HCl than at pH 2.5 and 5 (Figures 6-9). At 1N HCl the t1/2 
values for the intraconversion of amoxicillin ProD 1 and cephalexin ProD 1 were about 2.5 
hours and that of amoxicillin ProD 2 and cephalexin ProD 2 were about 7 and 6 hours, 
respectively. On the other hand, at pH 7.4, both prodrugs amoxicillin ProD 1-2 and 
cephalexin ProD 1-2 were quite stable and no release of the parent drugs was observed. At 
pH 5 the hydrolysis of prodrugs amoxicillin ProD 1-2 and cephalexin ProD 1-2 was too 
slow. This is because the pKa of amoxicillin ProD 1-2 and cephalexin ProD 1-2 is in the 
range of 3-4 and it is expected that at pH 5 the anionic form of the prodrug will be dominant 
and the percentage of the free acidic form that undergoes an acid-catalyzed hydrolysis will be 
relatively low. In 1N HCl and pH 2.5 most of the prodrug will exist as the free acid form and 
while at pH 7.4 most of the prodrug will be in the anionic form. The discrepancy in rates 
between amoxicillin ProD 1 and amoxicillin ProD 2 at the different pH buffers is attributed 
to the strain effects imposed in the case of amoxicillin ProD 1, which upon cleavage provides 
maleic anhydride while in the case of amoxicillin ProD 2, the byproduct is the less-strained 
succinic anhydride. The same picture is also applied for the discrepancy between cephalexin 
ProD 1 and cephalexin ProD 2. It is worth noting that previous DFT calculations 
[48]
 and 
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experimental data 
[41]
 on the acid-catalyzed hydrolysis of 1-9 revealed that the efficiency of 
the intramolecular acid-catalyzed hydrolysis by the carboxyl group is remarkably sensitive to 
the pattern of substitution on the carbon–carbon double bond. The rate of hydrolysis was 
found to be linearly correlated with the strain energy of the tetrahedral intermediate or the 
product. Systems having strained tetrahedral intermediates or products experience low rates 
and vice versa.  
 
Table 1: Observed k and t1/2 values for the intraconversion of amoxicillin ProD 1-ProD 2 
in 1N HCl and buffers pH 2.5, 5.0 and 7.4. 
 
 
 
 
 
 
Table 2: Observed k and t1/2 values for the intraconversion of cephalexin ProD 1-ProD 2 
in 1N HCl and buffers pH 2.5, 5.0 and 7.4. 
 
 
 
 
 
 
 
 
 
t 1/2  (h) k obs (h
-1
) t 1/2  (h) k obs (h
-1
) Medium 
Amoxicillin 
ProD 2 
Amoxicillin 
ProD 2 
Amoxicillin 
ProD 1 
Amoxicillin 
ProD 1 
 
8.2 8.37 x 10 
-5
 2.5 2.33 x 10 
-4
 1 N HCl 
44 1.54 x 10 
-5
 7 9.60 x 10 
-5
 Buffer pH 2.5 
---- No reaction 81 7.55 x 10
-6
 Buffer pH 5.0 
---- No reaction ---- No reaction Buffer pH 7.4 
t 1/2  (h) k obs (h
-1
) t 1/2  (h) k obs (h
-1
) Medium 
Cephalexin 
ProD 2 
Cephalexin 
ProD 2 
Cephalexin 
ProD 1 
Cephalexin 
ProD 1 
 
6 11.38 x 10 
-5
 2.4 2.41 x 10 
-4
 1 N HCl 
--- No reaction 14 4.17 x 10 
-5
 Buffer pH 2.5 
--- No reaction ---- No reaction Buffer pH 5.0 
---- No reaction ---- No reaction Buffer pH 7.4 
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Figure 6:  First order hydrolysis plot of amoxicillin ProD 1 in (a) 1N HCl, (b) buffer pH 
2.5 and (c) buffer pH 5.0. 
 
 
Figure 7: First order hydrolysis plot of amoxicillin ProD 2 in (a) 1N HCl and (b) buffer 
pH 2.5. 
 
 
Figure 8: First order hydrolysis plot of cephalexin ProD 1 in (a) 1N HCl and (b) buffer 
pH 2.5. 
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Figure 9: First order hydrolysis plot of cephalexin ProD 2 in 1N HCl. 
 
CONCLUSIONS AND FUTURE DIRECTIONS 
The future of prodrug design is forthcoming yet extremely challenging. Progresses must be 
made in better understanding the chemistry of many organic mechanisms that can be 
effectively exploited to push forward the development and advances of even more types of 
prodrugs. The understanding of the organic reactions mechanisms of intramolecular 
processes will be the next major milestone in this field. It is envisioned that the future of 
prodrug design holds the ability to produce safe and efficacious delivery of a wide range of 
active small molecule and biotherapeutics.  
 
Based on Kirby‘s enzyme model, we utilized two linkers for making novel prodrugs of 
amoxicillin and cephalexin, with the expectation to have prodrugs lacking the bitter sensation 
of their parent drugs as well as to be cleaved in different rates. The quantum mechanics (QM) 
calculations using different methods revealed that the acid-catalyzed hydrolysis efficiency of 
processes 1-9, amoxicillin ProD 1-2 and cephalexin ProD 1-2 is significantly sensitive to the 
pattern of substitution on the carbon-carbon double bond and nature of the amine leaving 
group. According to DFT calculations, the four antibacterial prodrugs will exist as a free 
carboxylic acid form (a relatively high lipophilicity) in the stomach, whereas in the blood 
circulation system, the carboxylate anion form (a relatively low lipophilicity) will be 
predominant. The synthesized prodrugs, amoxicillin ProD 1-2 and cephalexin ProD 1-2, 
were found to undergo hydrolysis in acidic aqueous medium, whereas they were stable at pH 
7.4. The predicted t1/2 and kobs of amoxicillin ProD 1-2 and cephalexin ProD 1-2 were 
calculated. Kinetics studies on the interconversion of the newly synthesized amoxicillin and 
cephalexin prodrugs revealed that the t1/2 was largely affected by the pH medium as 
predicted.  
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In vitro binding test has shown that the four antibacterial prodrugs, amoxicillin ProD1-
ProD2 and cephalexin ProD1-ProD2, do not bind to bitter taste receptors. It is believed that 
the addition of the linker (maleic or succinic promoiety) to amoxicillin and cephalexin 
hinders the ability and capability of the prodrug to interact with the active sites of the bitter 
taste receptors. In addition, in vitro antibacterial testing of amoxicillin ProD 2 and cephalexin 
ProD 2 demonstrated that both prodrugs possess strong antibacterial activity against a variety 
of bacteria.
[117] 
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